Association of antibody induction with short- and long- term cause-specific mortality in renal transplant recipients

Journal of the American Society of Nephrology

Volumn 13, Issue 3, 2002, Pages 769-772

  Meier Kriesche, Herwig Ulf ^a   Arndorfer, Julie A ^a   Kaplan, Bruce ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; LYMPHOCYTE ANTIBODY; OKT 3; THYMOCYTE ANTIBODY;

ADULT; AGE; ANTIBODY PRODUCTION; ARTICLE; CAUSE OF DEATH; COLD STRESS; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DISEASE ASSOCIATION; FEMALE; GENDER; GRAFT FAILURE; HLA MATCHING; HUMAN; INFECTION COMPLICATION; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 0036186410     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sequential antilymphoblast globulin and cyclosporine for renal transplantation
2. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy
3. A randomized clinical trial of induction therapy with OKT 3 in kidney transplantation
4. Improved results using OKT 3 as induction immunosuppression in renal allograft recipients with delayed graft function
5. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function
6. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data
7. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients
8. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients
9. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center
10. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression
11. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
12. CMV in kidney transplantation: A single center experience over 22 years
13. Hospitalizations for bacterial septicemia after renal transplantation in the united states
14. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT 3 after renal transplantation
15. Procoagulant and platelet aggregating properties of antilymphocyte sera
16. Monocyte procoagulant activity induced by in vivo administration of the OKT 3 monoclonal antibody
17. Acute thrombosis of the renal transplant artery after a single dose of OKT3
18. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant